Original work in the field of myocardial recovery generated by our lab led to the founding and establishment of the award winning Utah Cardiac Recovery Program – UCAR. To investigate the mechanisms implicated in myocardial recovery our lab is following a “bedside to bench and back” approach using human myocardial tissue findings from cardiac recovery patients to guide our basic science investigations which include knockout, inhibition or overexpression strategies in vitro and in vivo (small and large animal models). With this approach we identified (a) MCT4 inhibition, (b) VDAC2 activation, (c) the glucose accessory pathways (pentose-phosphate and 1-carbon metabolism) and (d) RUNX1 inhibition as novel therapeutic targets for myocardial recovery in chronic heart failure.